文献速递临床试验与 GCP流行病学与生物统计

急性缺血性卒中血管内取栓术后强化与常规降压治疗:OPTIMAL-BP随机临床试验

Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

该多中心随机开放标签盲法终点试验在韩国19个卒中中心纳入306例大血管闭塞急性缺血性卒中患者,取栓成功再灌注后分别接受强化降压(收缩压<140 mm Hg)或常规降压(收缩压140-180 mm Hg)24小时。强化组3个月功能独立比例低于常规组(39.4% vs 54.4%),风险差-15.1%(95%CI -26.2%至-3.9%),校正OR 0.56(95%CI 0.33-0.96;P=0.03)。作者认为取栓成功后应避免强化降压。

要点

  • 取栓成功再灌注后强化降压(收缩压<140 mm Hg)24小时,3个月功能独立比例低于常规降压(收缩压140-180 mm Hg)。
  • 强化组功能独立39.4%,常规组54.4%,风险差-15.1%(95%CI -26.2%至-3.9%),校正OR 0.56(95%CI 0.33-0.96;P=0.03)。
  • 症状性颅内出血和卒中相关死亡两组无显著差异;作者认为取栓成功后应避免强化降压。

核心结论

  • 在大血管闭塞急性缺血性卒中经血管内取栓成功再灌注的患者中,24小时强化降压较常规降压降低3个月功能独立可能性。
  • 作者认为急性缺血性卒中取栓成功后应避免强化降压。

研究设计与样本

  • 多中心、随机、开放标签、盲法终点评估试验,在韩国19个卒中中心开展,2020年6月至2022年11月入组,最终随访2023年3月8日。
  • 纳入306例大血管闭塞急性缺血性卒中经血管内取栓且改良脑梗死溶栓评分2b或以上(部分或完全再灌注)的患者。
  • 参与者随机接受强化降压(收缩压目标<140 mm Hg;n=155)或常规降压(收缩压目标140-180 mm Hg;n=150)24小时。
  • 试验因数据与安全监查委员会基于安全顾虑的建议而提前终止;306例随机患者中305例确认合格,302例(99.0%)完成试验(平均年龄73.0岁;女性122例[40.4%])。

主要发现

  • 强化组达到功能独立(改良Rankin量表评分0-2)的比例为39.4%,常规组为54.4%,风险差-15.1%(95%CI -26.2%至-3.9%),校正OR 0.56(95%CI 0.33-0.96;P=0.03)。
  • 症状性颅内出血发生率强化组9.0%,常规组8.1%,风险差1.0%(95%CI -5.3%至7.3%),校正OR 1.10(95%CI 0.48-2.53;P=0.82)。
  • 3个月内卒中相关死亡强化组7.7%,常规组5.4%,风险差2.3%(95%CI -3.3%至7.9%),校正OR 1.73(95%CI 0.61-4.92;P=0.31)。

关键数值与推荐

  • 强化降压目标:收缩压<140 mm Hg,持续24小时。
  • 常规降压目标:收缩压140-180 mm Hg,持续24小时。
  • 主要结局:3个月功能独立,定义为改良Rankin量表评分0-2。
  • 主要安全结局:36小时内症状性颅内出血和3个月内卒中相关死亡。

临床怎么用

  • 作者认为急性缺血性卒中血管内取栓成功再灌注后应避免强化降压。

局限性

  • 试验因数据与安全监查委员会基于安全顾虑的建议而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Optimal blood pressure (BP) control after successful reperfusion with endovascular thrombectomy (EVT) for patients with acute ischemic stroke is unclear. OBJECTIVE: To determine whether intensive BP management during the first 24 hours after successful reperfusion leads to better clinical outcomes than conventional BP management in patients who underwent EVT. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label trial with a blinded end-point evaluation, conducted across 19 stroke centers in South Korea from June 2020 to November 2022 (final follow-up, March 8, 2023). It included 306 patients with large vessel occlusion acute ischemic stroke treated with EVT and with a modified Thrombolysis in Cerebral Infarction score of 2b or greater (partial or complete reperfusion). INTERVENTIONS: Participants were randomly assigned to receive intensive BP management (systolic BP target <140 mm Hg; n = 155) or conventional management (systolic BP target 140-180 mm Hg; n = 150) for 24 hours after enrollment. MAIN OUTCOMES AND MEASURES: The primary outcome was functional independence at 3 months (modified Rankin Scale score of 0-2). The primary safety outcomes were symptomatic intracerebral hemorrhage within 36 hours and death related to the index stroke within 3 months. RESULTS: The trial was terminated early based on the recommendation of the data and safety monitoring board, which noted safety concerns. Among 306 randomized patients, 305 were confirmed eligible and 302 (99.0%) completed the trial (mean age, 73.0 years; 122 women [40.4%]). The intensive management group had a lower proportion achieving functional independence (39.4%) than the conventional management group (54.4%), with a significant risk difference (-15.1% [95% CI, -26.2% to -3.9%]) and adjusted odds ratio (0.56 [95% CI, 0.33-0.96]; P = .03). Rates of symptomatic intracerebral hemorrhage were 9.0% in the intensive group and 8.1% in the conventional group (risk difference, 1.0% [95% CI, -5.3% to 7.3%]; adjusted odds ratio, 1.10 [95% CI, 0.48-2.53]; P = .82). Death related to the index stroke within 3 months occurred in 7.7% of the intensive group and 5.4% of the conventional group (risk difference, 2.3% [95% CI, -3.3% to 7.9%]; adjusted odds ratio, 1.73 [95% CI, 0.61-4.92]; P = .31). CONCLUSIONS AND RELEVANCE: Among patients who achieved successful reperfusion with EVT for acute ischemic stroke with large vessel occlusion, intensive BP management for 24 hours led to a lower likelihood of functional independence at 3 months compared with conventional BP management. These results suggest that intensive BP management should be avoided after successful EVT in acute ischemic stroke. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04205305.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Nam HS, Kim YD, Heo J, et al. Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial. JAMA. 2023. PMID: 37668619. doi:10.1001/jama.2023.14590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。